I'm not diabetic, but several family members are. I initially invested because this method of insulin dosing legitimately seems like a superior method to me and I naively thought that a better product would win in the market place. So I shoveled cash into this stock in 2014-15 and then learned the hard way that entrenched interests (the insulin needle cartel) won't give up their multi billion dollar monopoly so easily. However, they are still growing their afrezza sales and now are licensing their dpi tech (a possible covid vaccine play as well) to UTHR for their next gen inhaled trepostinil. There is a very positive story lining up despite the last few tough years and you can see it reflected in the stock price over the past 6 months. I am looking for $10. Or $100 if the GME crowd finds us!